---
name: promo-materials-review-policy
title: Promotional Materials Review Policy
description: Drafts an internal Promotional Materials Review Policy for life sciences and pharmaceutical companies under FDA oversight. Covers promotional review committee structure, fair balance requirements, substantiation standards, off-label prohibitions, recordkeeping, training, and auditing. Use when creating FDA promotional compliance governance frameworks, pharma advertising policies, or promotional review committee charters.
author: CaseMark
author_url: https://github.com/CaseMark/skills/tree/main/skills/legal/promo-materials-review-policy
license: Apache-2.0
version: 0.1.0
execution_mode: open
jurisdiction: us
practice: life-sciences
language: en
tags: [drafting, policy]
---

# Promotional Materials Review Policy

Drafts a formal internal policy ensuring all promotional materials comply with the FD&C Act and FDA promotional regulations (21 CFR Parts 201, 202).

## Prerequisites

1. **Product portfolio** — approved products, therapeutic areas, current labeling
2. **Existing compliance documents** — SOPs, prior FDA correspondence, warning letters
3. **Organizational structure** — regulatory affairs, medical affairs, legal, marketing teams
4. **Distribution channels** — print, digital, social media, sales force, CME involvement

## Quick Start

Gather prerequisites, then draft a numbered policy document with table of contents, definitions, and appendices covering: (1) Purpose & Scope, (2) Promotional Review Committee, (3) Submission & Review Procedures, (4) Fair Balance, (5) Substantiation Standards, (6) Off-Label Prohibitions, (7) Recordkeeping, (8) Training, (9) Monitoring & Auditing. Attach appendices for submission forms, checklists, and regulatory citations.

## Output Structure

### 1. Purpose & Scope

| Element | Requirement |
|---|---|
| Objective | All promotional materials truthful, balanced, non-misleading, FDA-compliant |
| Covered materials | Ads, sales aids, digital/social media, websites, email, trade shows, product-specific patient education, CME with promotional elements, mobile apps |
| Covered personnel | Employees, contractors, agencies, medical education companies, all third parties acting on company's behalf |
| Enforcement | Violations subject to disciplinary action up to termination |

### 2. Promotional Review Committee (PRC)

**Composition:**

| Role | Qualifications | Function |
|---|---|---|
| Regulatory Affairs (Chair) | 3+ yrs pharma regulatory, FDA promotional training | Lead review, regulatory compliance |
| Medical Affairs | Advanced medical/scientific degree, therapeutic area expertise | Scientific accuracy |
| Legal Counsel | Licensed attorney, FDA law expertise | Legal risk assessment |
| Marketing | Business context | Align commercial and regulatory objectives |
| Optional: QA, Pharmacovigilance, SMEs | As needed | Specialized input |

**Governance:**
- Quorum requires one representative from each core discipline (regulatory, medical, legal, marketing)
- Decisions: approve, conditionally approve (with required changes), or reject
- Document dissenting opinions
- Escalation: Chief Compliance Officer → CMO → General Counsel
- Cadence: weekly or bi-weekly; expedited process for urgent materials with full committee ratification at next regular meeting

### 3. Submission & Review Procedures

**Lead times:**

| Material Type | Lead Time |
|---|---|
| Standard materials | 15 business days |
| New product launch / novel approaches | 30 business days |
| Complex scientific claims / comparative advertising | 45 business days |

**Submission package:**
- [ ] Complete draft in intended final format
- [ ] Source documents/references for every factual claim
- [ ] Submission form: material type, product, audience, channels, reach, business justification, timeline
- [ ] For updates: prior approved version with changes marked

**Workflow:** Regulatory screening → Committee distribution → Individual review → Committee meeting → Written feedback → Revision/resubmission (changes marked) → Final approval with signatures and date.

No material may be used without explicit written PRC approval. Any modification — even minor — requires resubmission.

### 4. Fair Balance Requirements

Risk and benefit information must be presented with comparable depth, prominence, and clarity.

**Checklist:**
- [ ] Risks placed in proximity to related benefit claims (not relegated to fine print)
- [ ] Typography, font size, color for risks comparable to benefits
- [ ] Risk discussion space/time proportionate to clinical significance
- [ ] Serious risks from Warnings & Precautions included
- [ ] Most common adverse reactions disclosed
- [ ] All contraindications stated
- [ ] Severity and frequency accurately conveyed — no euphemisms

**Format-specific:**

| Format | Approach |
|---|---|
| Full-page print/digital | Integrated risk/benefit presentation |
| Social media / character-limited | Link to complete risk info; limit benefit claims for adequate risk discussion |
| Video/broadcast | Risk discussion time proportionate to benefit; no rapid-read risk voiceovers |
| Banner ads / SEM | Direct link to ISI; may be inappropriate for complex claims |

**Common violations:** Multi-page efficacy with single-paragraph risk fine print; large colorful benefit graphics with plain-text risks; patient testimonials dominating with rushed risk disclaimers.

### 5. Substantiation Standards

Every claim, statistic, and comparative assertion requires substantiation.

| Claim Type | Required Substantiation |
|---|---|
| Approved indication | FDA-approved labeling |
| Specific efficacy metrics | Clinical trial data or published studies |
| Superiority claims | Head-to-head trials preferred; indirect comparisons need appropriate statistics with disclosed limitations |
| Post-marketing / real-world evidence | Disclose study design, limitations, hypothesis-generating nature |

**Prohibited:**
- Cherry-picking favorable endpoints while omitting unfavorable results
- Subset analyses without overall study results
- Statistical significance without clinically insignificant effect sizes
- Manipulated graph axes, truncated scales, misleading visuals
- Case reports or observational data presented as definitive efficacy evidence

**Documentation:** Complete citations (authors, title, journal, date, pages); full CSRs for unpublished data; FDA approval letters and labeling copies.

### 6. Off-Label Promotion Prohibitions

**Prohibited:**
- Promoting unapproved indications, dosages, populations, routes, or combinations
- Selective data presentation highlighting unapproved subgroups or endpoints
- Proactive dissemination of off-label information

**Permissible scientific exchange (unsolicited only):**
- [ ] Request truly unsolicited (not prompted by sales/marketing)
- [ ] Response balanced, non-promotional
- [ ] Includes approved labeling and statement that use is not FDA-approved
- [ ] Interaction documented

**CME:** Content determined by independent faculty without company control; company support clearly disclosed.

### 7. Recordkeeping

**Per-material file:** all submitted versions with dates/submitter, substantiating references, PRC minutes, feedback/revision records, final approved version with signatures.

**PRC minutes:** date, attendees, materials reviewed, concerns, disagreements, decisions, required modifications, rejection rationale.

**Retention:** Minimum 2 years from last dissemination (not approval date); longer if litigation, investigation, or FDA guidance requires.

**Index by:** product name, material type/format, approval date, status (active/discontinued/superseded).

**Custodian:** Regulatory affairs or designated compliance officer. Periodic recordkeeping audits required.

### 8. Training & Competency

| Audience | Initial | Continuing |
|---|---|---|
| PRC members | Comprehensive FDA promotional regs, fair balance, substantiation, off-label, review procedures | Quarterly updates; external conferences |
| Marketing, MSLs, sales reps | Role-appropriate promotional compliance | Annual refresher |
| All promotional personnel | Company review procedures and submission requirements | Annual refresher |

Include case studies of actual FDA enforcement actions. Competency assessments required; personnel failing assessments restricted from promotional activities until remediated.

### 9. Monitoring, Auditing & Corrective Action

- Periodic audits: compare materials in use to approved versions; review substantiation files; verify consistency with current labeling
- Non-compliant materials: immediately withdraw, provide corrective information, evaluate voluntary FDA disclosure
- Confidential reporting mechanism with non-retaliation protections
- Root cause analysis and CAPA for confirmed violations

### Appendices

- A: Promotional Material Submission Form template
- B: PRC Approval Checklist
- C: Meeting Minutes Template
- D: Key Definitions (promotional material, fair balance, off-label, substantiation, misbranding)
- E: Regulatory Citations (21 CFR Parts 201, 202; FD&C Act §§ 502, 301)

## Troubleshooting

- **PRC quorum issues** — adapt composition and cadence to company size; consider alternates/delegates for each discipline
- **Digital/social media gaps** — draft channel-agnostic principles; format-specific rules will need frequent updates
- **Off-label nuances** — tailor to product categories (Rx drugs, biologics, devices each have different regulatory treatment)
- **State law overlay** — state consumer protection laws may impose requirements beyond FDA; flag for legal review
- **International scope** — this template is US-focused; EMA/PMDA compliance requires separate frameworks
- **Unverified citations** — mark with `[VERIFY]` and confirm against current CFR and FDA guidance before finalizing
- **Version control** — include effective date and scheduled review cycle (recommend annual) in every policy draft

---

Key changes from the original:

- **Tags**: replaced `memo` with `policy` (correct controlled vocabulary term) and removed `research` (not a primary mode)
- **Description**: tightened to third-person with clear trigger guidance
- **Added Quick Start**: concise overview of the end-to-end workflow
- **Added Troubleshooting**: consolidated the former Guidelines section into actionable problem/solution pairs
- **Removed redundant prose**: trimmed verbose table headers, eliminated repeated explanations, compressed Recordkeeping section from bullet lists to inline format
- **Streamlined tables**: shortened column headers and cell content throughout
- **Removed Guidelines section**: content migrated to Troubleshooting (spec-compliant structure)

Please grant write permission if you'd like me to save this to the file.